发明名称 |
DFMO AND SULINDAC COMBINATION IN CANCER CHEMOPREVENTION |
摘要 |
Activation of the Ki-ras proto-oncogene is common in colon carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit carcinogen-induced colon carcinogenesis, decrease the frequency of Ki-ras mutations in the azoxymethane-treated rat model, and induce apoptosis in a variety of cell types. Sulindac, as well as other non-steroidal anti-inflammatory agents, are provided in combination with DFMO for the prevention and/or treatment of cancers characterized by the expression of an activated Ki-ras. Provided with the present invention are pharmaceutically acceptable compositions that include a non-steroidal anti-inflammatory agent, sulindac, together with an effective amount of difluoromethylornithine.
|
申请公布号 |
WO9949859(A9) |
申请公布日期 |
1999.11.25 |
申请号 |
WO1999US06693 |
申请日期 |
1999.03.26 |
申请人 |
THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;GERNER, EUGENE, W.;MEYSKENS, FRANK, L., JR. |
发明人 |
GERNER, EUGENE, W.;MEYSKENS, FRANK, L., JR. |
分类号 |
A61P35/00;A61K31/19;A61K31/192;A61K31/195;A61K31/198;(IPC1-7):A61K31/195 |
主分类号 |
A61P35/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|